Diagnostic pathology is a strong application area for AI, but it is not simply an image-classification problem. A useful system must work across scanners, stains, laboratories, patient populations, and clinical workflows—while giving pathologists evidence they can review. The most reliable projects begin with a narrow clinical question, carefully governed data, and prospective evaluation rather than a large model trained on loosely labelled slides.
Start with a clinically precise use case
Define the decision the model will support before choosing an architecture. “Detect cancer” is too broad; a buildable objective might be “flag suspicious regions for invasive breast carcinoma on H&E whole-slide images” or “quantify tumour percentage for a specified tissue type.” Establish:
- User and workflow: Is the tool for a pathologist, laboratory technician, tumour board, or triage team?
- Output: Will it produce a binary result, heatmap, count, grade, measurement, or ranked review queue?
- Reference standard: Decide whether labels come from consensus pathologists, immunohistochemistry, molecular tests, follow-up, or a combination.
- Acceptable error: In screening or triage, missed disease may be more harmful than extra reviews; thresholds must reflect that.
- Deployment setting: Account for government hospitals, private laboratories, telepathology networks, and smaller centres with variable infrastructure.
A narrow, measurable task is easier to validate, explain, and submit for clinical review. If your product will serve India’s diverse language and access needs, principles from building AI apps for the next billion users in India are also relevant to interface design, connectivity, and support operations.
Build a trustworthy pathology dataset
Whole-slide images (WSIs) can be extremely large, and their labels often contain uncertainty. Treat data curation as a clinical programme, not a preprocessing step.
- Collect representative cases: Include different hospitals, scanners, stain protocols, tissue quality, disease prevalence, and demographic groups. A single laboratory split can hide serious domain shift.
- Prevent patient leakage: Split at the patient level, never by tiles. If slides from one patient appear in both training and test sets, performance will be overstated.
- Record provenance: Store specimen type, staining method, scanner, magnification, laboratory, diagnosis source, and timestamp alongside each image.
- Use layered annotation: Start with slide-level labels for weak supervision, then add region-level or cellular annotations for a carefully selected subset. Record disagreements rather than forcing false certainty.
- Handle rare findings deliberately: Enrich rare positive cases, but report the original prevalence and test performance at clinically realistic prevalence.
For Indian deployments, establish a data-governance plan covering consent or permitted secondary use, de-identification, access controls, retention, audit logs, and cross-institutional sharing. Involve the institutional ethics committee and hospital data-protection teams early. Do not upload identifiable slides or reports to public services merely for experimentation.
Choose an architecture that matches the task
A practical pathology pipeline usually has several stages: slide quality control, tissue detection, tiling, feature extraction, aggregation, and clinical output. Common options include:
- CNNs and vision transformers: Useful for patch-level classification, segmentation, and feature extraction.
- Multiple-instance learning: Aggregates tile-level evidence when only slide-level labels are available.
- Self-supervised pretraining: Learns morphology from unlabelled local slides before fine-tuning on a specific task.
- Segmentation models: Suitable for nuclei, glands, tumour regions, necrosis, or tissue compartments.
- Classical models: Logistic regression, random forests, or gradient boosting can be effective on engineered features and are often easier to audit.
Begin with a transparent baseline before adopting a large foundation model. Compare the model against simple clinical rules and pathologist performance. Use open-source computer-vision practices, such as those described in how to build computer vision models on GitHub, but adapt them to WSI tiling, stain variation, and medical validation rather than treating natural-image benchmarks as sufficient evidence.
Preprocess without destroying clinical signal
Standardise inputs carefully. Tissue detection should exclude blank background and scanning artefacts, while quality-control checks should identify folds, blur, bubbles, pen marks, out-of-focus regions, and incomplete tissue. Stain normalisation can reduce technical variation, but aggressive normalisation may remove meaningful morphology. Compare several methods and retain original images for auditability.
Use augmentation to reflect plausible variation—moderate colour changes, rotations, crops, and blur—rather than manufacturing unrealistic pathology. Keep augmentation parameters independent of the test set. For large slides, use overlap and multi-scale tiles where clinically justified, then aggregate predictions with a method that preserves localisation and confidence.
Train, validate, and stress-test properly
Accuracy alone is inadequate. Track sensitivity, specificity, positive and negative predictive value, F1 score, area under the ROC curve, and—where prevalence is low—precision-recall performance. For measurements and counts, report calibration, correlation, and clinically acceptable error ranges. Include confidence intervals and subgroup results.
Use a development design that reflects deployment:
- Training set: Used for fitting parameters.
- Validation set: Used for model selection and threshold tuning.
- Internal test set: Locked until final evaluation.
- External test set: Drawn from different laboratories, scanners, or regions.
- Prospective or silent evaluation: Run in the real workflow without influencing decisions before clinical release.
Stress-test scanner changes, stain variation, small biopsies, poor-quality slides, uncommon subtypes, and missing metadata. Evaluate calibration, not just ranking. A model that is accurate on average but confidently wrong on a particular hospital is unsafe. Monitor performance drift after deployment and define a process for updating the model without silently changing its behaviour.
Design human oversight and explainability
The first product should usually be a decision-support tool, not an autonomous diagnostician. Show the evidence behind a result: highlighted regions, representative tiles, measurements, uncertainty, and relevant quality warnings. Make it easy for a pathologist to reject the suggestion and record the reason. Explanations should be clinically inspectable, not merely generic saliency maps.
Define escalation rules. Low-confidence cases, out-of-distribution slides, and failed quality checks should go to manual review. The interface must clearly distinguish an algorithmic suggestion from a confirmed diagnosis. Train users on limitations, document intended use, and test whether the tool changes turnaround time or diagnostic accuracy—not merely whether users like it.
Engineer for Indian clinical deployment
A research notebook is not a product. Plan for whole-slide storage, secure image transfer, viewer integration, authentication, audit trails, model versioning, and downtime procedures. Depending on the site, inference may need to run on-premises or in a controlled private cloud. Design for intermittent connectivity and limited hardware where necessary.
A useful deployment package includes:
- A slide-ingestion and quality-control service.
- A versioned inference pipeline with reproducible preprocessing.
- A viewer that links predictions to slide coordinates.
- Monitoring for latency, failed jobs, confidence, and data drift.
- A rollback mechanism and documented incident response.
- APIs that integrate with laboratory information systems without duplicating patient identifiers.
If several specialised components coordinate—such as ingestion, quality control, inference, and reporting—use explicit contracts and observability. Lessons from building distributed systems with AI agents can inform orchestration, but clinical systems should favour deterministic workflows, strict permissions, and human approval over autonomous agent behaviour.
Address regulation, safety, and evidence
Classify the intended product and obtain specialist regulatory and legal advice before clinical use. Prepare technical documentation covering intended purpose, training data, risk analysis, performance, cybersecurity, usability, change control, and post-market monitoring. In India, engage the relevant institutional, clinical, and regulatory stakeholders early; requirements may differ based on whether the system is research-only, laboratory software, or a medical device.
Run a formal hazard analysis. Consider false negatives, false positives, automation bias, cyberattacks, model updates, data loss, and misuse outside the validated population. Publish limitations clearly. Independent review, reproducible evaluation, and external validation will strengthen both clinical trust and grant applications.
A practical build sequence
1. Select one clinical decision and define the intended user.
2. Secure governance approvals and create a data dictionary.
3. Assemble a multi-site dataset with patient-level splits.
4. Establish a simple, auditable baseline.
5. Add quality control, localisation, and uncertainty estimates.
6. Validate externally and analyse subgroup performance.
7. Conduct silent prospective testing in the target workflow.
8. Integrate with the laboratory system and train users.
9. Launch narrowly with monitoring, rollback, and review checkpoints.
10. Expand only when new evidence supports the broader indication.
Conclusion
The central challenge in diagnostic pathology AI is not selecting the newest model. It is building a reliable chain from specimen to label, prediction, review, and clinical action. Teams that combine pathologists, laboratory scientists, ML engineers, data-governance specialists, and hospital IT leaders are best placed to produce systems that are accurate, usable, and safe. For India-focused builders, local validation and operational fit matter as much as benchmark scores.
FAQ
Can a small team build a pathology AI prototype?
Yes. Start with a tightly scoped, de-identified dataset, a baseline model, and retrospective evaluation. Clinical deployment requires substantially more evidence, governance, integration, and monitoring.
How many slides are needed?
There is no universal number. Diversity, label quality, disease prevalence, and independent external testing matter more than a large count from one laboratory. Rare conditions generally require multi-centre collaboration.
Should we use tiles or whole-slide models?
Tiles are more manageable for early experiments, while multiple-instance or hierarchical methods can aggregate slide-level evidence. The choice depends on annotation depth, compute, and the required output.
Can AI replace pathologists?
For most diagnostic workflows, AI should support qualified professionals. Human review, accountability, and escalation remain essential, especially for uncertain or out-of-distribution cases.
Where can Indian teams seek support?
Teams can explore AI Grants India for relevant funding opportunities, while also approaching hospitals, pathology networks, academic labs, and public health programmes for validation partnerships.